Key information

🔎 Fund Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. SL-172154 is in an ongoing Phase I clinical trial for the treatment of patients with ovarian cancer. It is also evaluating SL-172154 in an ongoing Phase I clinical trial for the treatment of patients with certain hematologic malignancies, including acute myeloid leukemia (AML), and higher-risk myelodysplastic syndromes (HR-MDS). The Company is also advancing a Gamma Delta T Cell Engager, GADLEN platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.